Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AB1 | P08238 | 13/20 | 0.56 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.56 |
| ▸ | HSP90AA1 | P07900 | 4/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4258586 | 0.86 | HSP90AB1 (0.48) | HSP90AB1KCNH2HSP90AA1CYP2C19LMNA | |
| SCHEMBL4089936 | 0.84 | HSP90AB1 (0.60) | HSP90AB1KCNH2HSP90AA1CYP2C19 | |
| SCHEMBL4094869 | 0.81 | HSP90AB1 (0.46) | HSP90AB1KCNH2HSP90AA1CYP2C19POLB | |
| SCHEMBL13765764 | 0.78 | HSP90AB1 (0.47) | HSP90AB1HSP90AA1CYP2C19LMNA | |
| SCHEMBL4091000 | 0.74 | HSP90AB1 (0.51) | HSP90AB1KCNH2HSP90AA1CYP2C19 | |
| SCHEMBL2562465 | 0.72 | HSP90AB1 (1.00) | HSP90AB1KCNH2HSP90AA1CYP2C19 | |
| SCHEMBL13765766 | 0.69 | TSHR (0.50) | CYP2C19LMNAPOLB | |
| SCHEMBL3961277 | 0.67 | HSP90AA1 (0.83) | HSP90AB1KCNH2HSP90AA1CYP2C19 | |
| SCHEMBL3958250 | 0.67 | HSP90AB1 (1.00) | HSP90AB1KCNH2HSP90AA1 | |
| SCHEMBL3961384 | 0.66 | HSP90AB1 (0.92) | HSP90AB1KCNH2HSP90AA1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090181989-A1 | Purine Compunds as HSP90 Protein Inhibitors for the Treatment of Cancer | VERNALIS ( R & D) LTD. (GB) | 2009-07-16 | — | — | US | disclosed |
| US-20090181989-A1 | Purine Compunds as HSP90 Protein Inhibitors for the Treatment of Cancer | VERNALIS ( R & D) LTD. (GB) | 2009-07-16 | — | — | US | disclosed |
| US-20090181989-A1 | Purine Compunds as HSP90 Protein Inhibitors for the Treatment of Cancer | VERNALIS ( R & D) LTD. (GB) | 2009-07-16 | — | — | US | disclosed |
| WO-2007034185-A1 | PURINE COMPOUNDS AS HSP90 PROTEIN INHIBITORS FOR THE TREATMENT OF CANCER | VERNALIS (R & D) LTD. (GB) | 2007-03-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090181989-A1 | Purine Compunds as HSP90 Protein Inhibitors for the Treatment of Cancer | HSP90AA1, HSP90AB1, HSP90AB2P | HSP90AB1 2/4885KCNH2 3508/4885HSP90AA1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.